Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 337 | 73 | 255 |
| Samples | 274 | 60 | 206 |
| Peptides | 242 | 48 | 194 |
Function
UHRF2 · Ubiquitin like with PHD and ring finger domains 2
This gene encodes a nuclear protein which is involved in cell-cycle regulation. The encoded protein is a ubiquitin-ligase capable of ubiquinating PCNP (PEST-containing nuclear protein), and together they may play a role in tumorigenesis. The encoded protein contains an NIRF_N domain, a PHD finger, a set- and ring-associated (SRA) domain, and a RING finger domain and several of these domains have been shown to be essential for the regulation of cell proliferation. This protein may also have a role in intranuclear degradation of polyglutamine aggregates. Alternative splicing results in multiple transcript variants some of which are non-protein coding. [provided by RefSeq, Feb 2012].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 237 amino-acid changes on canonical ENST00000276893 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in UHRF2 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in UHRF2 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 19/612 3% |
| Burkitts Lymphoma | 2/32 6% | 1/196 1% |
| Neuroendocrine Tumour | 7/154 5% | 2/577 0% |
| Bladder Carcinoma | 3/58 5% | 9/956 1% |
| Melanoma | 2/210 1% | 22/1899 1% |
| Colorectal Carcinoma | 9/143 6% | 28/3239 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Non-Small Cell Lung Carcinoma | 4/304 1% | 12/1390 1% |
| Cervical Carcinoma | 0/35 0% | 4/422 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Glioma | 3/52 6% | 11/2127 1% |
| Rhabdomyosarcoma | 0/33 0% | 1/171 1% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Prostate Carcinoma | 0/13 0% | 10/2105 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 12/2550 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Breast Carcinoma | 2/144 1% | 13/3264 0% |
| Mesothelioma | 1/62 2% | 0/165 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| B-Cell Non-Hodgkins Lymphoma | 7/88 8% | 3/2534 0% |
| Other Solid Cancers | 2/94 2% | 4/1515 0% |
| Hepatocellular Carcinoma | 0/46 0% | 8/2210 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 4/1592 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
Mutation Distribution
Where UHRF2 is mutated · all tissues, split by cell line vs tissue
How many mutations in UHRF2 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 337 mutations in UHRF2
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|